Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Searching for universal utility
July/August 2020
SHARING OPTIONS:

BILTHOVEN, Netherlands & LOWELL, Mass.—Intravacc and Versatope have teamed up in pursuit of developing a universal vaccine against influenza, one that will be based on Intravacc’s Outer Membrane Vesicles (OMV) technology. The U.S. Centers for Disease Control and Prevention report that flu vaccines had an overall effectiveness of just 29 percent during the 2018-2019 flu season due to new strains emerging late in the season. Per the agreement, Intravacc will offer its services to Versatope to help advance VT-105, Versatope’s universal influenza vaccine candidate, toward clinical trials. Financial details were not disclosed.
 
“We are very happy to partner with Versatope and to be able to further expand the global reach of our OMV technology. This partnership is dedicated to finding in a much-needed universal flu vaccine,” said Dr. Jan Groen, CEO of Intravacc.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.